Objective: To compare the successful of the identification of the ureteral orifice at cervical cancer patients who received phenazopyridine orally and to analyze the correlation between hydronephrosis and successful rate for retrograde stenting. Material & Method: This was a comparative experimental study, using phenazopyridine hcl orally prior to cystoscopy to identify the ureteral orifice on cervical cancer patients and to perform retrograde stenting on spotted ureteral orifice. Forty samples provided consent to enroll in this study. Mean age was 49.2 ± 5.16 years. Thirty-four out of 40 samples was confirmed as squamous cell carcinoma type. Results: Chi-square test demonstrated no significant differentiation in finding ureteral orifice between treatment and control group on stage 3B (p = 0.408). However, result shown conversely on stage 4A (p = 0.046). There was no significant disparity in conducting retrograde stenting between treatment and control group on stage 2B and 3B (p = 0.221 and p = 0.197). There was no significant correlation between hydronephrosis gradation and retrograde stenting on control group (p = 0.144). Conclusion: Administration of phenazopyridine HCL orally in cervical cancer patients increase success for ureteral orifice identification and retrograde stenting, but not statistically significant. There is no correlation between hydronephrosis with a success retrograde stenting.Keywords: Cervical cancer, hydronephrosis, phenazopyridine hcl, ureteral orifice, retrograde stenting.
Cervical cancer, hydronephrosis, phenazopyridine hcl, ureteral orifice, retrograde stenting
Aziz MF. Gynecological cancer in Indonesia. Journal Gynecol Onco. 2009; 20(1): 8-10.
Sundar S, Horne A, Kehoe S. Cervical Cancer. BMJ Clinical Evidence. 2008; (3)818.
Data pasien kanker mulut rahim Poli Onkologi Ginekologi RSUD Dr. Soetomo Surabaya; 2010.
Suarsana IW, Soebadi DM. Profil penderita Malignant Ureteral Obstruction akibat kanker mulut rahim yang dirawat di Rumah Sakit Umum Daerah dr. Soetomo Surabaya tahun 2007 sampai tahun 2009. 2012. p. 18-19.
Russo P. Urological emergencies in the cancer patient. Seminars in Oncology 2000; 27: 284.
McIntyre JE, Eifel PJ, Levenback C. Ureteral stricture as a late complication of radiotherapy for stage 1b carcinoma of the uterine cervix. Cancer. 1995; 75: 836.
Kouba E, Wallen EM, Pruthi RS. Management of ureteral obstruction due to advanced malignancy: Optimizing therapeutic and palliative outcomes. The Journal of Urology. 2008; 180: 444-50.
College of American Pathologists. Cervical cancer. Cervical squamous cell carcinoma, 2011. (accessed September 29, 2013) Available from http://www.cap.org/apps/docs/reference/myBiopsy/cervicalsquamous.pdf
Prat J, Damjanov I. Tumors of the female genital organs. In: Damjanov I and Fan F, eds, 2nd ed. Cancer Grading Manual. Berlin Heidelberg: Springer-Verlag, 2013. p. 109-18.
Rohan TE. The epidemiology of adenocarcinoma of the cervix. In: Rohan TE and Shah KV, eds. Cervical Cancer: from Etiology to Prevention. Dordrecht: Kluwer academic publishers; 2004. p. 217-29.
BC Cancer Agency. Invasive – Squamous cell carcinoma and adenocarcinoma, 2013. (accessed September 29, 2013) Available from http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Gynecology/UterineCervix1of2/Management/Invasive.htm
De Oliveira CF, Mota F. Cervical cancer – pre therapeutic investigations and clinical staging ‘versus” surgical staging. CME Journal of Gynecologic Oncology. 2001; 6: 246-56.
Chitale SV, Scott-Barrett S, Ho ETS, Burgess NA. The management of ureteric obstruction secondary to malignant pelvic disease. Clinical Radiology. 2002; 57: 1118-21.